通过特定合并症和癫痫病因来评估布瓦西坦 (BRV) 对成人癫痫患者的有效性和耐受性。EXPERIENCE/EPD332 是对临床实践中癫痫患者启动 BRV 的几项非干预性研究中的个体患者记录的汇总分析。结果包括癫痫发作频率较基线降低 50%、无癫痫发作（前 3 个月内无癫痫发作）、持续无癫痫发作（自基线后无癫痫发作）、BRV 停药以及治疗后第 3、6、6 小时出现的不良事件 (TEAE)和 12 个月。对所有成年患者（≥16 岁）进行分析，并按基线时的合并症和病因进行分层（患有认知/学习障碍 [CLD]、精神合并症、中风后癫痫、脑肿瘤相关癫痫 [BTRE] 的患者）和创伤性脑损伤相关癫痫 [TBIE]）。12 个月时，癫痫发作减少了 35.6% (n = 264)、38.7% (n = 310)、41.7% (n = 24)、34.1患有 CLD、精神共病、中风后癫痫、BTRE 和 TBIE 的患者分别占 % (n = 41) 和 50.0% (n = 28)；持续无癫痫发作的比例分别为 5.7% (n = 318)、13.7% (n = 424)、29.4% (n = 34)、11.4% (n = 44) 和 13.8% (n = 29)。在研究随访期间，患有 CLD、精神共病、中风后癫痫、BTRE 和 TBIE 的患者中，分别为 37.1% (n = 403)、30.7% (n = 605)、33.3% (n = 51)、39.7分别有 % (n = 68) 和 27.1% (n = 49) 的患者停止 BRV；自上次就诊以来 12 个月内发生 TEAE 的比例分别为 11.3% (n = 283)、10.0% (n = 410)、16.7% (n = 36)、12.5% (n = 48) 和 3.0% (n = 33) ），分别。在现实世界中，BRV 在患有 CLD、精神共病、中风后癫痫、BTRE 和 TBIE 的患者中是有效且耐受性良好的。© 2024。作者。

To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies.EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor-related epilepsy [BTRE], and traumatic brain injury-related epilepsy [TBIE]).At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (n = 264), 38.7% (n = 310), 41.7% (n = 24), 34.1% (n = 41), and 50.0% (n = 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n = 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (n = 44), and 13.8% (n = 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n = 403), 30.7% (n = 605), 33.3% (n = 51), 39.7% (n = 68), and 27.1% (n = 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n = 283), 10.0% (n = 410), 16.7% (n = 36), 12.5% (n = 48), and 3.0% (n = 33), respectively.BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.© 2024. The Author(s).